Anavex Life Sciences Corp (AVXL)

[XenaLives]

From the AI response..

AI overviews are experimental. Learn more
Altered filamin A (FLNA) is a scaffolding protein that is linked to Alzheimer's disease (AD) and amyloid and tau pathologies. A 2017 study found that altered FLNA is prevalent in AD brains and is induced by amyloid beta (Aß). The study also found that altered FLNA is required for two prominent pathogenic signaling pathways of Aß.

PubMed
Altered filamin A enables amyloid beta-induced tau hyperphosphorylation and neuroinflammation in Alzheimer's disease
A DNA change that alters the blueprint for making the FLNA protein can result in an abnormally short version of the protein. Researchers suspect that this altered protein may not be able to interact with other molecules normally. This inability to bind to other proteins can disrupt important processes involved in skeletal development and cell growth, leading to bone and skin abnormalities.

FLNA is highly expressed in the brain, and its protein interactions are regulated by mechanical forces, phosphorylation, cleavage, and other factors. An altered conformation of FLNA would likely alter certain protein interactions or induce aberrant ones.

So since it is a plaque attack drug it seems that it would not be needed if Anavex drugs can intercept the disease process before plaque is formed.